Pamplona, Spain – March 11, 2021 – Telum Therapeutics, a leading biotechnology company specializing in drug discovery, is pleased to announce the grant of European Patent EP4118192A1, titled “New Recombinant Lysin and Its Use in the Treatment of Gram-Negative Bacterial Infections.” This patent strengthens Telum’s position in developing innovative lysin-based therapies to combat infections caused by multidrug-resistant Gram-negative bacteria.
The patent protects Telum’s proprietary recombinant lysin technology, which is designed to selectively degrade the bacterial cell wall, offering a novel and highly targeted alternative to traditional antibiotics. This breakthrough is particularly crucial in addressing antimicrobial resistance (AMR), a pressing global health challenge.
“The granting of this European patent is a major milestone for Telum Therapeutics,” said Dr. Roberto Díez, CEO of Telum. “It validates our pioneering work in developing recombinant lysins as a new generation of precision antimicrobials and reinforces our commitment to tackling the growing threat of multidrug-resistant infections.”
Telum Therapeutics specializes in developing engineered phage-derived lysins as next-generation antimicrobial agents. By leveraging the natural bactericidal activity of lysins, Telum is advancing a new paradigm in infection treatment that circumvents traditional antibiotic resistance mechanisms.
For more information about Telum Therapeutics and its recent developments, please visit https://telumtherapeutics.com/our-science/pipeline/.